Recombinant human parathyroid hormone (1-34): Pro-osteogenic action and application in oral field
10.3969/j.issn.2095-4344.2731
- Author:
Xiling DONG
1
Author Information
1. Department of Prosthodontics, Binzhou Medical University Hospital
- Publication Type:Journal Article
- Keywords:
Implant-osseointegration;
Jaw;
Osteoporosis;
Periodontal;
Recombinant human parathyroid hormone (1-34);
Stomatology;
Teriparatide
- From:
Chinese Journal of Tissue Engineering Research
2020;24(26):4231-4236
- CountryChina
- Language:Chinese
-
Abstract:
BACKGROUND: Recombinant human parathyroid hormone 1-34 (rhPTH 1-34), also known as teriparatide, is the amino terminal fragment of parathyroid hormone. Teriparatide, as a bone anabolic drug, has become a research hotspot because it can directly stimulate new bone formation and increase bone mass. It also attracts attention and application in the oral field due to its strong osteogenesis effect. OBJECTIVE: To review the osteogenic mechanisms, efficacy and safety of teriparatide and its research progress in the oral field. METHODS: The first author searched the PubMed and WanFang databases for relevant literature published over the past two decades. The keywords were “rhPTH(1-34); teriparatide; osteoporosis; stomatology; Jaw; implant-osseointegration; periodontal” in English and Chinese, respectively. Fifty-six eligible articles were finally reviewed. RESULTS AND CONCLUSION: Teriparatide can directly stimulate the formation of osteoblasts in new bone and achieve effective anabolic metabolism. Studies of teriparatide in the oral field have shown good results in promoting implant-osseointegration, periodontal regeneration, bone defect healing and the stability of orthodontics, but increasing high-quality animal experiments and clinical studies are still needed. Future use of parathyroid hormone drugs and their analogues can be combined with bone tissue engineering technology to provide favorable effects in bone repair as well as in oral and maxillofacial repair.
